VIPR1

Across TCGA pan-cancer cohorts, VIPR1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of VIPR1’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where VIPR1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types VIPR1 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where VIPR1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VIPR1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	−1.796	<.001	9	view →
LUAD	Male	All	−1.389	<.001	9	view →
HNSC	Male	III,IV	−0.986	<.001	6	view →
COAD	All	All	−0.823	.005	6	view →
CCRCC	Male	IV	+1.723	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

VIPR1–LSCC

Open the LSCC breakdown →